Your AI-Trained Oncology Knowledge Connection!
Hope S. Rugo, MD, FASCO, discusses how elacestrant, an oral selective estrogen receptor degrader, demonstrated superior progression-free survival compared with standard endocrine therapy in patients with ER+/HER2– metastatic breast cancer (MBC) who had previously received CDK4/6 inhibitors in the phase 3 EMERALD trial.
A panelist discusses how combining elacestrant with targeted therapies like CDK4/6 inhibitors or PI3K inhibitors could potentially enhance its efficacy and overcome resistance mechanisms in ER+/HER2– MBC treatment.
Hope S. Rugo, MD, FASCO, discusses how the phase 3 ELEVATE study evaluates the combination of elacestrant with abemaciclib in patients with ER+/HER2– advanced or MBC who have progressed on prior endocrine therapy.
Hope S. Rugo, MD, FASCO, highlights key data from the ELEVATE study, presented at SABCS 2024.
A panelist discusses how the phase 2 ELECTRA trial studies elacestrant in combination with ribociclib as first-line therapy for ER+/HER2– advanced breast cancer in postmenopausal women.
Hope S. Rugo, MD, FASCO, discusses the role of abemaciclib plus elacestrant for ER+/HER2– MBC from data presented at SABCS 2024.
A panelist discusses how comprehensive molecular testing at MBC diagnosis, including genomic profiling and ESR1 mutation status, helps guide treatment decisions and identify potential therapeutic targets.
A panelist discusses how molecular testing for patients with MBC who relapse during or shortly after adjuvant endocrine therapy is crucial for detecting ESR1 mutations and other resistance mechanisms that can inform subsequent treatment selection.
Hope S. Rugo, MD, FASCO, discusses how circulating tumor DNA testing enables real-time monitoring of disease progression, detection of emerging mutations, and assessment of treatment response in patients with MBC.
A panelist discusses how molecular testing results, including ESR1 mutations, PIK3CA alterations, and other genomic findings, directly inform treatment decisions and sequencing of therapies for patients with MBC.
Hope S. Rugo, MD, FASCO, discusses key takeaways from SABCS 2024 conference.
